MAPK1 and head and neck squamous cell carcinoma: We next evaluated the antitumoral activity of the ERK-mTOR targeting combination therapy in vivo, using UM-SCC-17B and Detroit 562 HNSCC xenografts, which harbor endogenous activating HRAS and PIK3CA mutations, respectively.